Terms: = Prostate cancer AND TCF7L2, ENSG00000148737, 6934, TCF-4 AND Treatment
3 results:
1. RANKL immunisation inhibits prostate cancer metastasis by modulating EMT through a RANKL-dependent pathway.
Park M; Cho YJ; Kim B; Ko YJ; Jang Y; Moon YH; Hyun H; Lim W
Sci Rep; 2021 Jun; 11(1):12186. PubMed ID: 34108600
[TBL] [Abstract] [Full Text] [Related]
2. Ormeloxifene Suppresses prostate Tumor Growth and Metastatic Phenotypes via Inhibition of Oncogenic β-catenin Signaling and EMT Progression.
Hafeez BB; Ganju A; Sikander M; Kashyap VK; Hafeez ZB; Chauhan N; Malik S; Massey AE; Tripathi MK; Halaweish FT; Zafar N; Singh MM; Yallapu MM; Chauhan SC; Jaggi M
Mol Cancer Ther; 2017 Oct; 16(10):2267-2280. PubMed ID: 28615299
[TBL] [Abstract] [Full Text] [Related]
3. Positive inter-regulation between beta-catenin/T cell factor-4 signaling and endothelin-1 signaling potentiates proliferation and survival of prostate cancer cells.
Sun P; Xiong H; Kim TH; Ren B; Zhang Z
Mol Pharmacol; 2006 Feb; 69(2):520-31. PubMed ID: 16291872
[TBL] [Abstract] [Full Text] [Related]
